Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James Goodrich

Showing results (21-30 of 35) with videos related to

Pageof 4
Sort By:
Journal of Acquired Immune Deficiency Syndromes (1999)|January 15, 2014
Five-year safety evaluation of maraviroc in HIV-1-infected treatment-experienced patientsRoy M Gulick, Gerd Fatkenheuer, Robert Burnside, et al.
Journal of Clinical and Translational Science|December 10, 2024
Fielding the research participant perception survey to evaluate a culturally tailored Latinx cohort studySierra Lindo, Jamie Roberts, James Goodrich, et al.
AIDS (London, England)|October 12, 2010
Hepatic safety and tolerability in the maraviroc clinical development programAyman Ayoub, Sam Alston, James Goodrich, et al.
HIV Clinical Trials|August 26, 2010
Efficacy and safety of maraviroc versus efavirenz, both with zidovudine/lamivudine: 96-week results from the MERIT studyJuan Sierra-Madero, Giovanni Di Perri, Robin Wood, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|January 19, 2013
Efficacy and safety of lersivirine (UK-453,061) versus efavirenz in antiretroviral treatment-naive HIV-1-infected patients: week 48 primary analysis results from an ongoing, multicenter, randomized, double-blind, phase IIb trialPietro Vernazza, Cunshan Wang, Anton Pozniak, et al.
The American Journal of Pathology|August 6, 2019
Double-Stranded RNA Is a Novel Molecular Target in Osteomyelitis Pathogenesis: A Translational Avian Model for Human Bacterial Chondronecrosis with OsteomyelitisElizabeth Greene, Joshua Flees, Ahmed Dhamad, et al.
Lancet (London, England)|April 10, 2016
Ixmyelocel-T for patients with ischaemic heart failure: a prospective randomised double-blind trialAmit N Patel, Timothy D Henry, Arshed A Quyyumi, et al.
The Journal of Infectious Diseases|July 5, 2005
Molecular and clinical epidemiology of CXCR4-using HIV-1 in a large population of antiretroviral-naive individualsZabrina L Brumme, James Goodrich, Howard B Mayer, et al.
Antimicrobial Agents and Chemotherapy|October 2, 2013
Genotypic analysis of the V3 region of HIV from virologic nonresponders to maraviroc-containing regimens reveals distinct patterns of failureLuke C Swenson, Celia K S Chui, Chanson J Brumme, et al.
The New England Journal of Medicine|October 4, 2008
Maraviroc for previously treated patients with R5 HIV-1 infectionRoy M Gulick, Jacob Lalezari, James Goodrich, et al.
Pageof 4

Showing results (21-30 of 35) with videos related to

Sort By:
Pageof 4
Journal of Acquired Immune Deficiency Syndromes (1999)|January 15, 2014
Five-year safety evaluation of maraviroc in HIV-1-infected treatment-experienced patientsRoy M Gulick, Gerd Fatkenheuer, Robert Burnside, et al.
Journal of Clinical and Translational Science|December 10, 2024
Fielding the research participant perception survey to evaluate a culturally tailored Latinx cohort studySierra Lindo, Jamie Roberts, James Goodrich, et al.
AIDS (London, England)|October 12, 2010
Hepatic safety and tolerability in the maraviroc clinical development programAyman Ayoub, Sam Alston, James Goodrich, et al.
HIV Clinical Trials|August 26, 2010
Efficacy and safety of maraviroc versus efavirenz, both with zidovudine/lamivudine: 96-week results from the MERIT studyJuan Sierra-Madero, Giovanni Di Perri, Robin Wood, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|January 19, 2013
Efficacy and safety of lersivirine (UK-453,061) versus efavirenz in antiretroviral treatment-naive HIV-1-infected patients: week 48 primary analysis results from an ongoing, multicenter, randomized, double-blind, phase IIb trialPietro Vernazza, Cunshan Wang, Anton Pozniak, et al.
The American Journal of Pathology|August 6, 2019
Double-Stranded RNA Is a Novel Molecular Target in Osteomyelitis Pathogenesis: A Translational Avian Model for Human Bacterial Chondronecrosis with OsteomyelitisElizabeth Greene, Joshua Flees, Ahmed Dhamad, et al.
Lancet (London, England)|April 10, 2016
Ixmyelocel-T for patients with ischaemic heart failure: a prospective randomised double-blind trialAmit N Patel, Timothy D Henry, Arshed A Quyyumi, et al.
The Journal of Infectious Diseases|July 5, 2005
Molecular and clinical epidemiology of CXCR4-using HIV-1 in a large population of antiretroviral-naive individualsZabrina L Brumme, James Goodrich, Howard B Mayer, et al.
Antimicrobial Agents and Chemotherapy|October 2, 2013
Genotypic analysis of the V3 region of HIV from virologic nonresponders to maraviroc-containing regimens reveals distinct patterns of failureLuke C Swenson, Celia K S Chui, Chanson J Brumme, et al.
The New England Journal of Medicine|October 4, 2008
Maraviroc for previously treated patients with R5 HIV-1 infectionRoy M Gulick, Jacob Lalezari, James Goodrich, et al.
Pageof 4